{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:25Z","timestamp":1740107425990,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00393-021-01154-5","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T12:03:17Z","timestamp":1642766597000},"page":"280-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapie-Update der ANCA-assoziierten Vaskulitiden: Granulomatose mit Polyangiitis und Mikroskopische Polyangiitis","Update on treatment of ANCA-associated vasculitis: Granulomatosis with polyangiitis and Microscopic Polyangiitis"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1086-1034","authenticated-orcid":false,"given":"Julia U.","family":"Holle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-1801","authenticated-orcid":false,"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-9844","authenticated-orcid":false,"given":"Frank","family":"Moosig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"1154_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone\u00a0JH, Merkel\u00a0PA, Spiera\u00a0RSP et al (2010) Rituximab versus Cyclophosphamide for ANCA-associated Vasculitis. N\u00a0Engl J Med 363:221\u2013132","journal-title":"N Engl J Med"},{"issue":"5","key":"1154_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks\u00a0U, Merkel\u00a0PA, Seo\u00a0P et al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N\u00a0Engl J Med 369(5):417\u2013427","journal-title":"N Engl J Med"},{"issue":"4","key":"1154_CR3","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1681\/ASN.2014010046","volume":"26","author":"D Geetha","year":"2015","unstructured":"Geetha\u00a0D, Specks\u00a0U, Stone\u00a0JH et al (2015) Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J\u00a0Am Soc Nephrol 26(4):976\u2013985","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1154_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung\u00a0SA, Langford\u00a0CA, Maz\u00a0M et al (2021) 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 73(8):1366\u20131383","journal-title":"Arthritis Rheumatol"},{"issue":"3 Suppl 97","key":"1154_CR5","first-page":"S54","volume":"4","author":"G Pugnet","year":"2016","unstructured":"Pugnet\u00a0G, Pagnoux\u00a0C, Terrier\u00a0B et al (2016) Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life. Clin Exp Rheumatol 4(3 Suppl 97):S54\u2013S59","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"1154_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones\u00a0RB, Cohen Tervart\u00a0JW et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N\u00a0Engl J Med 363(3):211\u2013220","journal-title":"N Engl J Med"},{"issue":"1","key":"1154_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ndt\/gfx378","volume":"34","author":"SP Mcadoo","year":"2019","unstructured":"Mcadoo\u00a0SP, Medjeral-Thomas\u00a0N, Gopaluni\u00a0S et al (2019) Long-term follow-up of a\u00a0combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant 34(1):63\u201373","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1154_CR8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/rheumatology\/kez001","volume":"58","author":"RJ Pepper","year":"2019","unstructured":"Pepper\u00a0RJ, McAdoo\u00a0SP, Moran\u00a0SM et al (2019) A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 58(2):260\u2013268","journal-title":"Rheumatology"},{"issue":"7","key":"1154_CR9","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DRW Jayne","year":"2007","unstructured":"Jayne\u00a0DRW, Gaskin\u00a0G, Rasmussen\u00a0N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J\u00a0Am Soc Nephrol 18(7):2180\u20132188","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1154_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/ki.2013.131","volume":"84","author":"M Walsh","year":"2013","unstructured":"Walsh\u00a0M, Casian\u00a0A, Flossmann\u00a0O, EVSG (EUVAS) (2013) Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment ist unclear. Kidney Int 84(2):397\u2013402","journal-title":"Kidney Int"},{"issue":"7","key":"1154_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh\u00a0M, Merkel\u00a0PA, Peh\u00a0CA et al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N\u00a0Engl J Med 382(7):622\u2013631","journal-title":"N Engl J Med"},{"issue":"1","key":"1154_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-021-02415-z","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada\u00a0Y, Harada\u00a0M, Hara\u00a0Y et al (2021) Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a\u00a0systematic review and meta-analysis. Arthritis Res Ther 23(1):1\u201311","journal-title":"Arthritis Res Ther"},{"key":"1154_CR13","first-page":"687","volume":"2006","author":"DRW Jayne","year":"2021","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0T, ASG (2021) Avacopan for the treatment of ANCA-associated vasculitis. N\u00a0Engl J Med 2006:687\u2013696","journal-title":"N Engl J Med"},{"issue":"19","key":"1154_CR14","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin\u00a0L, Pagnoux\u00a0A, Karras\u00a0C et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N\u00a0Engl J Med 371(19):1771\u20131780","journal-title":"N Engl J Med"},{"issue":"8","key":"1154_CR15","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2017-212768","volume":"77","author":"B Terrier","year":"2018","unstructured":"Terrier\u00a0B, Pagnoux\u00a0C, Perrodeau \u00c9 et al (2018) Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77(8):1151\u20131157","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1154_CR16","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles\u00a0P, Terrier\u00a0B, Perrodeau \u00c9 et al (2018) Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a\u00a0multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77(8):1144\u20131150","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1154_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/M19-3827","volume":"73","author":"P Charles","year":"2020","unstructured":"Charles\u00a0P, Perrodeau\u00a0E, Samson\u00a0M et al (2020) Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a\u00a0randomized trial. Ann Intern Med 73(3):179\u2013187","journal-title":"Ann Intern Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01154-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-021-01154-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01154-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T11:07:33Z","timestamp":1651489653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-021-01154-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1154"],"URL":"https:\/\/doi.org\/10.1007\/s00393-021-01154-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"24 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B. Hellmich hat Vortragshonorare von Boehringer, GSK, Roche und Vifor sowie Honorare f\u00fcr Beratungsleistungen von InflaRx, GSK, Novartis, Roche und Vifor erhalten. J.U.\u00a0Holle und F.\u00a0Moosig geben an, dass in Bezug auf diesen Artikel kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}